UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 17, 2014
Keryx Biopharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 000-30929 | | 13-4087132 |
(State or Other Jurisdiction of Incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)
(212) 531-5965
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act. |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. |
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
A special meeting of stockholders of Keryx Biopharmaceuticals, Inc. (“Keryx” or the “Company”) was held on November 17, 2014. Stockholders voted to approve an amendment to the Company’s 2013 Incentive Plan to increase the number of authorized shares issuable thereunder from 3,500,000 to 9,500,000 (the “Amendment”).
The vote with respect to the Amendment is set forth below:
| | | | |
Total Votes For | | Total Votes Against | | Abstentions |
51,155,027 | | 3,953,134 | | 128,153 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| | | | Keryx Biopharmaceuticals, Inc. |
| | | | (Registrant) |
| | | |
| Date: November 17, 2014 | | | | By: | | /s/ James F. Oliviero |
| | | | James F. Oliviero |
| | | | Chief Financial Officer |
